首页> 外文OA文献 >Brigatinib for anaplastic lymphoma kinase-tyrosine kinase inhibitor naïve anaplastic lymphoma kinase-positive advanced non-small cell lung cancer: an effective but still broken option

【2h】

Brigatinib for anaplastic lymphoma kinase-tyrosine kinase inhibitor naïve anaplastic lymphoma kinase-positive advanced non-small cell lung cancer: an effective but still broken option

机译：Brigatinib用于促进淋巴瘤激酶 - 酪氨酸激酶抑制剂NaïveAnploplastic淋巴瘤激酶阳性晚期非小细胞肺癌：有效但仍然破裂的选择

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
Biagio Ricciuti; Giuseppe Lamberti; Fausto Roila; Giulio Metro;
展开▼
作者单位

展开▼
年度 2019
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. Comparative efficacy of brigatinib versus ceritinib and alectinib in patients with crizotinib-refractory anaplastic lymphoma kinase-positive non-small cell lung cancer [J] . Reckamp Karen, Lin Huamao M., Huang Joice, Current medical research and opinion . 2019,第4期

机译：Brigatinib对Creizotinib-Remplactory Anploplastic淋巴瘤激酶阳性非小细胞肺癌患者的比较疗效
2. Four lines of anaplastic lymphoma kinase inhibitors and brain radiotherapy in a long-surviving non-small-cell lung cancer anaplastic lymphoma kinase-positive patient with leptomeningeal carcinomatosis [J] . Concetta E. Onesti, Daniela Iacono, Silvia Angelini, Anti-cancer drugs . 2019,第2期

机译：四条血压淋巴瘤激酶抑制剂和脑放射治疗的长杂种非小细胞肺癌，含有百分之肌癌癌激素淋巴瘤激酶阳性患者
3. New treatment options and challenges for patients with anaplastic lymphoma kinase-positive non-small cell lung cancer with brain metastases [J] . Dwight Owen, Gregory A. Otterson Journal of Thoracic Disease . 2017,第2期

机译：具有脑转移的血糖淋巴瘤激酶阳性非小细胞肺癌患者的新治疗选择和挑战
4. Selective tyrosine kinase inhibitor, STI571, inhibitsgrowth of p53 mutant anaplastic thyroid cancer cellsby inducing S-G2 transition arrest [C] . Alexei P. Podtcheko, Satoshi Tsuda, Akira Ohtsuru International Consortium for Medical Care of Hibakusha and Radiation Life Science . 2003

机译：选择性酪氨酸激酶抑制剂，STI571，P53突变体的抑制性诱导S-G2过渡逮捕的抑制性甲状腺癌细胞
5. Understanding the function of the JunB transcription factor in anaplastic lymphoma kinase-positive, anaplastic large cell lymphoma. [D] . Pearson, Joel Dylan. 2013

机译：了解JunB转录因子在间变性淋巴瘤激酶阳性，间变性大细胞淋巴瘤中的功能。
6. Brigatinib for anaplastic lymphoma kinase-tyrosine kinase inhibitor naïve anaplastic lymphoma kinase-positive advanced non-small cell lung cancer: an effective but still broken option [O] . Biagio Ricciuti, Giuseppe Lamberti, Fausto Roila, 2019

机译：Brigatinib治疗间变性淋巴瘤激酶-酪氨酸激酶抑制剂未治疗的间变性淋巴瘤激酶阳性的晚期非小细胞肺癌：有效但仍无效的选择
7. Pharmacoeconomic analysis of ALK inhibitors in treatment of advanced or metastatic anaplastic lymphoma kinase-positive non-small cell lung cancer [O] . D.Yu. Belousov, A.E. Cheberda, E.V. Afanasieva, 2019

机译：治疗晚期或转移性促进淋巴瘤激酶阳性非小细胞肺癌治疗脯氨酸抑制剂的药物经济分析

Brigatinib for anaplastic lymphoma kinase-tyrosine kinase inhibitor naïve anaplastic lymphoma kinase-positive advanced non-small cell lung cancer: an effective but still broken option

著录项

引文网络

相似文献

相关主题

期刊订阅